CJC 1295 No DAC + Ipamorelin Blend
- Size
- 10mg
Specifications
CJC 1295 No DAC + Ipamorelin Blend Technical Profile
OVERVIEW
What Is CJC-1295 No DAC + Ipamorelin Blend?
The CJC-1295 No DAC + Ipamorelin blend combines two complementary growth hormone-related research peptides into a single formulation. CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic GHRH analog consisting of 29 amino acids with four amino acid substitutions that enhance metabolic stability. Ipamorelin is a selective pentapeptide growth hormone secretagogue receptor (GHS-R) agonist that mimics the action of ghrelin at the pituitary.
This CJC-1295 ipamorelin blend is designed for CJC-1295 growth hormone research studying the synergistic effects of simultaneous GHRH receptor and GHS-R activation. The CJC-1295 No DAC peptide stimulates GH release through the GHRH pathway, while ipamorelin engages the ghrelin/GHS-R pathway, two distinct but complementary mechanisms for promoting pulsatile growth hormone secretion. This dual-pathway approach has made the CJC-1295 ipamorelin blend one of the most popular research combinations for studying growth hormone axis regulation. Buy CJC-1295 ipamorelin from VivePeptides for ≥99% purity from a trusted USA supplier.
- 01
Dual GH Secretagogue Blend
GHRH analog + GHS-R agonist for synergistic GH axis research
- 02
≥99% HPLC Purity
Each component verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
CJC-1295 No DAC + Ipamorelin Mechanism of Action in Research
The CJC-1295 ipamorelin blend mechanism involves two distinct but synergistic pathways converging on pituitary somatotroph cells. CJC-1295 ipamorelin research has explored how simultaneous activation of these pathways amplifies growth hormone release in research models.
GHRH Receptor Pathway (CJC-1295 No DAC)
CJC-1295 No DAC binds to the GHRH receptor on pituitary somatotroph cells, activating the Gs-cAMP-PKA signaling cascade. This pathway promotes transcription of the GH gene and stimulates GH secretion from existing granule stores. The four amino acid substitutions in CJC-1295 No DAC (Ala2→D-Ala, Asn8→Ala, Ala15→Ala, Met27→Leu) provide resistance to enzymatic degradation while maintaining receptor binding affinity. CJC-1295 growth hormone research has documented pulsatile GH release patterns following GHRH-R activation.
GHS-R/Ghrelin Receptor Pathway (Ipamorelin)
Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. This pathway signals through Gq-phospholipase C-IP3 cascades, increasing intracellular calcium and promoting GH vesicle exocytosis. Ipamorelin is notable for its selectivity, unlike other GHS-R agonists, research indicates it produces minimal effects on ACTH, cortisol, or prolactin in research models (Raun et al., Endocrinology, 1998).
Synergistic Amplification
CJC-1295 ipamorelin research demonstrates that simultaneous GHRH-R and GHS-R activation can produce synergistic GH release exceeding the sum of individual responses. This synergy reflects the convergence of cAMP and calcium signaling pathways on common GH secretory mechanisms within somatotroph cells. ---
COMPARISON
CJC-1295 No DAC + Ipamorelin vs Standalone CJC-1295: Research Comparison
CJC-1295 No DAC + Ipamorelin
This comparison helps researchers determine whether the blend or standalone CJC-1295 No DAC is more appropriate for their specific experimental design.
Standalone CJC-1295
The CJC-1295 ipamorelin blend is ideal for researchers studying dual-pathway GH axis activation and synergistic GH release mechanisms. Standalone CJC-1295 No DAC is preferred when isolating GHRH-R pathway contributions. Both are available from VivePeptides at CJC-1295 ipamorelin purity of ≥99%.
| Feature | CJC-1295 No DAC + Ipamorelin Blend | CJC-1295 No DAC Standalone |
|---|---|---|
| Components | CJC-1295 No DAC + Ipamorelin | CJC-1295 No DAC only |
| Receptor Targets | GHRH-R + GHS-R (dual pathway) | GHRH-R only (single pathway) |
| GH Release Pattern | Synergistic, amplified pulsatile release | Standard GHRH-mediated pulsatile release |
| Selectivity | Both components selective for GH axis | Selective for GHRH pathway |
| Research Application | Synergy studies, dual-pathway GH research | Single-pathway GHRH research |
| Dose Optimization | Pre-blended for convenience | Flexible individual dosing |
| Complexity | Two-component system | Single-component system |
RESEARCH STUDIES
CJC-1295 No DAC + Ipamorelin Research Applications & Published Studies
CJC-1295 ipamorelin research draws from the published literature on each component peptide and their synergistic interaction in GH axis studies.
GHRH Analog Pharmacology
CJC-1295 growth hormone research is built on published studies of modified GRF(1-29) analogs. Studies have documented the pharmacokinetic improvements achieved through the four amino acid substitutions, demonstrating enhanced half-life and maintained receptor potency. Research published on the DAC (Drug Affinity Complex) version and the No DAC version provides comparative data on different GHRH analog strategies.
Ipamorelin Selectivity Studies
Raun et al. (Endocrinology, 1998) published pivotal research establishing ipamorelin's selectivity profile among GHS-R agonists. This study demonstrated that ipamorelin produced GH release without significant effects on other pituitary hormones, making it one of the most selective ghrelin mimetics available for research.
GH Axis Synergy Research
Published research on GHRH and GHRP co-administration has demonstrated the synergistic nature of simultaneous GHRH-R and GHS-R activation. Bowers et al. (Endocrine Reviews, 1991) documented that combined GHRH + GHS-R agonist administration produces GH release 2-5 fold greater than either compound alone, providing the scientific rationale for the CJC-1295 ipamorelin blend approach.
QUALITY ASSURANCE
Quality & Testing Standards
HPLC & Mass Spectrometry
Both CJC-1295 No DAC and ipamorelin undergo individual HPLC and mass spectrometry analysis to verify identity, purity, and molecular weight.
Third-Party Verified
All components are independently tested at third-party USA-based analytical laboratories.
≥99% Purity Standard
Each component consistently meets or exceeds ≥99% purity as verified by HPLC for reliable dual-pathway research.
FAQ
Frequently Asked Questions About CJC-1295 No DAC + Ipamorelin
What is CJC-1295 No DAC + Ipamorelin used for in research?
What purity is VivePeptides CJC-1295 No DAC + Ipamorelin?
How should CJC-1295 No DAC + Ipamorelin be stored?
What is the difference between CJC-1295 with DAC and CJC-1295 No DAC?
Is VivePeptides CJC-1295 No DAC + Ipamorelin third-party tested?
BPC-157
MOTS-c
Gastric pentadecapeptide for tissue biology research
Mitochondrial-derived peptide for metabolic research
Vive GLP(S)
GLP-1 receptor agonist for metabolic pathway research
Explore More Research Peptides
All Peptides → · Vive GLP(T) · Vive GLP(R) · NAD+ · GHK-Cu · Selank · SNAP-8 · BAC Water
Add To Research Cart
CJC 1295 No DAC + Ipamorelin Blend
99%+ purity · USA lab tested · secure shipping
You May Also Research
